Cytokinetics' (CYTK) Q1 Results Solid, BENEFIT Remains in Focus - Roth
Tweet Send to a Friend
Roth Capital has Cytokinetics (Nasdaq: CYTK) at Buy with a target price of $13 following Q1 results.After markets closed Tuesday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
